Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
October 30, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024...
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
October 17, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
September 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
August 08, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
August 07, 2024 07:40 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
August 07, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA’s strong prescription uptake continues: Q2...
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
July 24, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
June 18, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint...
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
June 10, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...